Raffaele Ornello Selected Research

erenumab

6/2022	European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.
3/2022	Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.
1/2022	Acute Medication Use in Patients With Migraine Treated With Monoclonal Antibodies Acting on the CGRP Pathway: Results From a Multicenter Study and Proposal of a New Index.
1/2022	Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.
8/2021	Early outcomes of migraine after erenumab discontinuation: data from a real-life setting.
3/2021	Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series.
1/2021	Association between response to triptans and response to erenumab: real-life data.
1/2021	Paralytic ileus after planned abdominal surgery in a patient on treatment with erenumab.
8/2020	Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region.
4/2020	Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Raffaele Ornello Research Topics

Disease

30	Migraine Disorders (Migraine) 06/2022 - 10/2013
13	Headache (Headaches) 06/2022 - 12/2015
6	Stroke (Strokes) 01/2022 - 01/2016
3	Ischemic Stroke 01/2022 - 01/2020
3	Secondary Headache Disorders 01/2022 - 05/2019
2	Atrial Fibrillation 01/2022 - 01/2021
2	Pain (Aches) 08/2021 - 01/2021
2	Mood Disorders (Mood Disorder) 06/2021 - 06/2021
2	Alzheimer Disease (Alzheimer's Disease) 06/2021 - 06/2021
2	Dementia (Dementias) 06/2021 - 06/2021
2	Cognitive Dysfunction 06/2021 - 06/2021
2	Cluster Headache (Cluster Headaches) 11/2020 - 11/2018
2	Prescription Drug Overuse 04/2020 - 10/2019
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Hemorrhage 01/2022
1	Substance-Related Disorders (Drug Abuse) 04/2021
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 04/2021
1	Genetic Predisposition to Disease (Genetic Predisposition) 04/2021
1	Severe Acute Respiratory Syndrome 01/2021
1	Cerebral Hemorrhage 01/2021
1	Post-Traumatic Headache 01/2021
1	Intestinal Pseudo-Obstruction (Intestinal Pseudoobstruction) 01/2021
1	Myasthenia Gravis 01/2020
1	Seizures (Absence Seizure) 01/2019
1	Epilepsy (Aura) 01/2019
1	Partial Epilepsies (Epilepsy, Partial) 01/2019
1	Tension-Type Headache (Tension Headache) 11/2018
1	Multiple Sclerosis 01/2018
1	Meningoencephalitis 01/2018
1	Brain Injuries (Brain Injury) 01/2018
1	Hypertension (High Blood Pressure) 09/2014

Drug/Important Bio-Agent (IBA)

12	erenumabIBA 06/2022 - 10/2019
9	Calcitonin Gene-Related PeptideIBA 06/2022 - 05/2019
9	Monoclonal AntibodiesIBA 06/2022 - 05/2019
5	Type A Botulinum Toxins (Botox)FDA Link 12/2021 - 04/2020
5	Tryptamines (Triptans)IBA 05/2021 - 01/2020
4	Pharmaceutical PreparationsIBA 01/2022 - 01/2019
4	Estrogens (Estrogen)FDA Link 05/2021 - 01/2015
3	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 01/2022 - 10/2019
3	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022 - 06/2021
2	fremanezumabIBA 06/2022 - 01/2022
2	salicylhydroxamic acid (SHAM)IBA 01/2022 - 11/2021
2	AnticoagulantsIBA 01/2022 - 01/2021
2	Glucose (Dextrose)FDA LinkGeneric 06/2021 - 06/2021
2	LipidsIBA 06/2021 - 06/2021
2	Analgesics (Analgesic Drugs)IBA 05/2021 - 04/2021
2	Gonadal Steroid Hormones (Sex Hormones)IBA 05/2021 - 11/2018
2	Hormones (Hormone)IBA 01/2021 - 11/2018
1	galcanezumabIBA 06/2022
1	eptinezumabIBA 06/2022
1	VaccinesIBA 01/2022
1	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 01/2022
1	Vitamin K FDA Link 01/2021
1	Local AnestheticsIBA 01/2021
1	SteroidsIBA 01/2021
1	SuspensionsIBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2020
1	AntibodiesIBA 01/2020
1	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 01/2020
1	Contraceptive Agents (Contraceptives)IBA 01/2020
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2019
1	Lacosamide FDA Link 01/2019
1	Levetiracetam (Keppra)FDA LinkGeneric 01/2019
1	Inflammation MediatorsIBA 01/2018
1	Myelin ProteinsIBA 01/2018
1	Complement System Proteins (Complement)IBA 01/2018
1	danaparoid (Orgaran)FDA Link 01/2018
1	Botulinum Toxins (Botulinum Toxin)IBA 12/2015
1	Angiotensin Receptor AntagonistsIBA 09/2014
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 09/2014
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 09/2014
1	Indicators and Reagents (Reagents)IBA 10/2013

Therapy/Procedure

3	Therapeutics 01/2022 - 01/2020
2	Secondary Prevention 01/2022 - 01/2016
2	Transcranial Direct Current Stimulation 01/2022 - 11/2021
2	Estrogen Replacement Therapy 01/2021 - 01/2015
2	Nerve Block (Nerve Blocks) 01/2021 - 11/2020
1	Duration of Therapy 01/2022
1	Injections 01/2021
1	Aftercare (After-Treatment) 09/2020
1	Contraindications 09/2014